The Russian pharmaceutical industry successfully competes with global leaders, developing and launching its own innovative drugs. This was stated by the head of the Ministry of Industry and Trade Anton Alikhanov in an interview with RIA Novosti.
According to the minister, domestic companies are not limited to the production of reproduced drugs, but are actively creating original developments. Thus, in October 2025, the company "Generium" registered the world's first drug with a new mechanism of action for the treatment of mucopolysaccharidosis type II - Hunter syndrome.
This disease is associated with metabolic disorders and damage to the nervous system. The new Russian drug is able to penetrate the barrier between the blood and nerve tissue, affecting neurological symptoms. Previously existing drugs could only eliminate the physical manifestations of the disease, without preventing the destruction of nerve cells.
Alikhanov stressed that the production of the new product will be carried out in Russia in a full cycle - from the synthesis of the substance to the finished form.